» Articles » PMID: 30371180

Fibroblast Growth Factor-23 and Heart Failure With Reduced Versus Preserved Ejection Fraction: MESA

Overview
Date 2018 Oct 30
PMID 30371180
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

Background Higher fibroblast growth factor-23 ( FGF -23) levels are associated with incident heart failure ( HF ) in MESA (the Multiethnic Study of Atherosclerosis). FGF -23 is also associated with left ventricular hypertrophy. Whether the FGF -23 association with HF is similar for heart failure with reduced ejection fraction ( HF r EF ) and heart failure with preserved ejection fraction ( HF p EF ) is not well established. Methods and Results We studied 6542 participants (mean age 62±10 years, 53% women, mean estimated glomerular filtration rate of 81±18 mL/min per 73 m) from MESA who were free of cardiovascular disease at baseline (2000-2002). HF events were ascertained by an adjudication committee for a median follow-up of 12.1 years. We classified HF events as HF r EF (ejection fraction [ EF ] <50%) or HF p EF [ EF ] ≥50%) at the time of diagnosis. Cox proportional hazard regression was used to compute hazard ratios and 95% confidence intervals for the association between baseline serum FGF -23 and incident HF r EF and HF p EF . A total of 134 events were classified as HF p EF , 151 HF r EF , and 49 unknown EF . Following imputation, 149 were classified as HF p EF , 176 HF r EF , and 291 participants had HF (34 participants had HF p EF then HF r EF ). In the fully adjusted model, higher FGF -23 levels were associated with incident HF p EF but not with HF r EF (hazard ratio 1.29, 95% confidence interval, 1.08-1.54) versus (hazard ratio 1.04, 95% confidence interval, 0.84-1.29) for each 20 pg/mL higher serum FGF -23 concentration. Conclusions FGF -23 association with HF is driven by the association with HF p EF but not with HF r EF in a population-based cohort. Further studies are needed to determine the pathological mechanisms mediating this association.

Citing Articles

A generalizable electrocardiogram-based artificial intelligence model for 10-year heart failure risk prediction.

Butler L, Karabayir I, Kitzman D, Alonso A, Tison G, Chen L Cardiovasc Digit Health J. 2024; 4(6):183-190.

PMID: 38222101 PMC: 10787146. DOI: 10.1016/j.cvdhj.2023.11.003.


Fibroblast Growth Factor 23 and Risk of Heart Failure Subtype: The CRIC (Chronic Renal Insufficiency Cohort) Study.

Leidner A, Cai X, Zelnick L, Lee J, Bansal N, Pasch A Kidney Med. 2023; 5(11):100723.

PMID: 37915961 PMC: 10616385. DOI: 10.1016/j.xkme.2023.100723.


Proteomic Correlates of the Urinary Protein/Creatinine Ratio in Heart Failure With Preserved Ejection Fraction.

Gan S, Zhao L, Salman O, Wang Z, Ebert C, Azzo J Am J Cardiol. 2023; 206:312-319.

PMID: 37734292 PMC: 10874232. DOI: 10.1016/j.amjcard.2023.08.146.


Heart failure in erythrodermic psoriasis: a retrospective study of 225 patients.

Wu C, Yu C, Yang Y, Jin H Front Cardiovasc Med. 2023; 10:1169474.

PMID: 37593148 PMC: 10427504. DOI: 10.3389/fcvm.2023.1169474.


Fibroblast growth factor-23 and the risk of cardiovascular diseases and mortality in the general population: A systematic review and dose-response meta-analysis.

Liu M, Xia P, Tan Z, Song T, Mei K, Wang J Front Cardiovasc Med. 2022; 9:989574.

PMID: 36407457 PMC: 9669381. DOI: 10.3389/fcvm.2022.989574.


References
1.
Fyfe-Johnson A, Alonso A, Selvin E, Bower J, Pankow J, Agarwal S . Serum fibroblast growth factor-23 and incident hypertension: the Atherosclerosis Risk in Communities (ARIC) Study. J Hypertens. 2016; 34(7):1266-72. PMC: 4950510. DOI: 10.1097/HJH.0000000000000936. View

2.
Larsson T, Marsell R, Schipani E, Ohlsson C, Ljunggren O, Tenenhouse H . Transgenic mice expressing fibroblast growth factor 23 under the control of the alpha1(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis. Endocrinology. 2004; 145(7):3087-94. DOI: 10.1210/en.2003-1768. View

3.
Inker L, Schmid C, Tighiouart H, Eckfeldt J, Feldman H, Greene T . Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med. 2012; 367(1):20-9. PMC: 4398023. DOI: 10.1056/NEJMoa1114248. View

4.
Bild D, Bluemke D, Burke G, Detrano R, Diez Roux A, Folsom A . Multi-Ethnic Study of Atherosclerosis: objectives and design. Am J Epidemiol. 2002; 156(9):871-81. DOI: 10.1093/aje/kwf113. View

5.
Dai B, David V, Martin A, Huang J, Li H, Jiao Y . A comparative transcriptome analysis identifying FGF23 regulated genes in the kidney of a mouse CKD model. PLoS One. 2012; 7(9):e44161. PMC: 3435395. DOI: 10.1371/journal.pone.0044161. View